AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
CHMP Momentum, Critical Medicines Act, HTA Capacity Scaling
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
CAAMP delivered eight approvals at their May meeting, including Neurandomolast for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. That brings them to 36 positive opinions year to date. The pulmonary fibrosis space is finally seeing movement after years of limited options.
SPEAKER_01Conditional approval for alpillicib and a PIK3CA-related overgrowth spectrum also caught my attention. These rare disease approvals are critical for establishing EU HTA precedents before the regulation expands. Each one tests how joint clinical assessments handle complex benefit-risk profiles in small populations.
SPEAKER_00The regulatory momentum is undeniable, but I'm watching how these approvals translate into HTA preparedness. 36 positive opinions means 36 potential JCA candidates once the scope expands. Are companies building dossiers that can handle both EMA's scientific standards and HTACG's clinical assessment framework?
SPEAKER_01That's the fundamental tension. EMA approval gets you market authorization, but it's no longer sufficient for access. The evidence packages that satisfy CHMP won't automatically work for joint clinical assessments. Companies need parallel evidence strategies from phase three planning forward.
SPEAKER_00The Critical Medicines Act reached provisional political agreement on May 12th. EMA welcomed it as building on their extended mandate to reinforce manufacturing capacity and supply resilience. This isn't just about availability, it's about creating a framework where critical medicines get prioritized treatment.
SPEAKER_01But here's where it gets interesting for market access. If medicines are designated as critical, do they get expedited HTA pathways? The Act focuses on supply chain resilience, but the commercial implications could be significant. Priority designation could mean faster joint clinical assessments or different benefit risk thresholds.
SPEAKER_00I'm not seeing evidence of expedited HTA treatment yet. The Act complements pharmaceutical legislation but doesn't explicitly create HTA fast tracks. We're still dealing with the same 17 scientific advice slots and capacity constraints.
SPEAKER_01True, but political agreements create momentum. If Parliament and Council prioritize supply resilience, that pressure flows to HTA bodies. The designation process could become a de facto access accelerator even without explicit pathways.
SPEAKER_00The HTAR capacity building program is expanding with five e-learning modules available in English plus six other EU languages starting end of May. This represents serious investment in sustainable HTA capacity ahead of the five-year expansion.
SPEAKER_01Multilingual capacity building is essential, but I question whether e-learning modules address the fundamental bottleneck. We need more assessors, more coordinators, more infrastructure. Training existing people better doesn't solve the throughput problem.
SPEAKER_00Fair point, but you have to build competency before you can scale personnel. These modules standardize assessment approaches across member states. Without common methodological foundations, adding more assessors just creates inconsistent outputs.
SPEAKER_01I'll grant you that standardization is necessary. But while we're building perfect training programs, companies are struggling with 17 scientific advice slots for all of Europe. The capacity constraints are immediate and growing worse as more sponsors recognize they need early HTA engagement.
SPEAKER_00The HTA Stakeholder Network membership got extended for all current members by another three years starting May 4th. No resignations from members or observers. That's remarkable stakeholder engagement in a system still finding its footing.
SPEAKER_01It shows confidence in the long-term framework, but also reveals how much work remains. Stakeholders are staying engaged because they recognize the system will eventually matter enormously for European access. But we're still in the early implementation phase with significant operational challenges.
SPEAKER_00AAAG estimates 35 joint clinical assessments for new oncology active substances and 15 ATMPs in 2026, plus the first five high-risk medical device assessments starting June. That's ambitious scaling from the current limited scope.
SPEAKER_01Those numbers highlight the disconnect between ambition and capacity.
SPEAKER_00The system is maturing, but operational realities are limiting actual impact. Companies are building parallel evidence strategies because they can't rely on EU HTA timelines aligning with commercial needs.
SPEAKER_01Exactly. Until capacity matches scope ambitions, EUHTA remains a valuable but unpredictable component of access strategies rather than the central coordinating mechanism it's designed to become.no.